165 related articles for article (PubMed ID: 20629598)
21. The cost effectiveness of genetic testing for CYP2C19 variants to guide thienopyridine treatment in patients with acute coronary syndromes: a New Zealand evaluation.
Panattoni L; Brown PM; Te Ao B; Webster M; Gladding P
Pharmacoeconomics; 2012 Nov; 30(11):1067-84. PubMed ID: 22974536
[TBL] [Abstract][Full Text] [Related]
22. Prasugrel: a review of its use in patients with acute coronary syndromes undergoing percutaneous coronary intervention.
Duggan ST; Keating GM
Drugs; 2009 Aug; 69(12):1707-26. PubMed ID: 19678718
[TBL] [Abstract][Full Text] [Related]
23. Optimizing P2Y12 receptor inhibition in patients with acute coronary syndrome on the basis of platelet function testing: impact of prasugrel and high-dose clopidogrel.
Aradi D; Tornyos A; Pintér T; Vorobcsuk A; Kónyi A; Faluközy J; Veress G; Magyari B; Horváth IG; Komócsi A
J Am Coll Cardiol; 2014 Mar; 63(11):1061-70. PubMed ID: 24486281
[TBL] [Abstract][Full Text] [Related]
24. Elderly patients with acute coronary syndromes managed without revascularization: insights into the safety of long-term dual antiplatelet therapy with reduced-dose prasugrel versus standard-dose clopidogrel.
Roe MT; Goodman SG; Ohman EM; Stevens SR; Hochman JS; Gottlieb S; Martinez F; Dalby AJ; Boden WE; White HD; Prabhakaran D; Winters KJ; Aylward PE; Bassand JP; McGuire DK; Ardissino D; Fox KA; Armstrong PW
Circulation; 2013 Aug; 128(8):823-33. PubMed ID: 23852610
[TBL] [Abstract][Full Text] [Related]
25. Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolysis In Myocardial Infarction) analysis.
Antman EM; Wiviott SD; Murphy SA; Voitk J; Hasin Y; Widimsky P; Chandna H; Macias W; McCabe CH; Braunwald E
J Am Coll Cardiol; 2008 May; 51(21):2028-33. PubMed ID: 18498956
[TBL] [Abstract][Full Text] [Related]
26. A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 Trial.
Angiolillo DJ; Badimon JJ; Saucedo JF; Frelinger AL; Michelson AD; Jakubowski JA; Zhu B; Ojeh CK; Baker BA; Effron MB
Eur Heart J; 2011 Apr; 32(7):838-46. PubMed ID: 21252171
[TBL] [Abstract][Full Text] [Related]
27. Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial.
Michelson AD; Frelinger AL; Braunwald E; Downey WE; Angiolillo DJ; Xenopoulos NP; Jakubowski JA; Li Y; Murphy SA; Qin J; McCabe CH; Antman EM; Wiviott SD;
Eur Heart J; 2009 Jul; 30(14):1753-63. PubMed ID: 19435740
[TBL] [Abstract][Full Text] [Related]
28. Pharmacodynamic effects of standard dose prasugrel versus high dose clopidogrel in non-diabetic obese patients with coronary artery disease.
Darlington A; Tello-Montoliu A; Rollini F; Ueno M; Ferreiro JL; Patel R; Desai B; Guzman LA; Bass TA; Angiolillo DJ
Thromb Haemost; 2014 Feb; 111(2):258-65. PubMed ID: 24154863
[TBL] [Abstract][Full Text] [Related]
29. Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis.
Mega JL; Close SL; Wiviott SD; Shen L; Walker JR; Simon T; Antman EM; Braunwald E; Sabatine MS
Lancet; 2010 Oct; 376(9749):1312-9. PubMed ID: 20801494
[TBL] [Abstract][Full Text] [Related]
30. Prasugrel for the treatment of patients with acute coronary syndrome.
Marzot F; Pengo V
Vasc Health Risk Manag; 2009; 5(1):321-4. PubMed ID: 19436677
[TBL] [Abstract][Full Text] [Related]
31. Pharmacodynamic effect of switching therapy in patients with high on-treatment platelet reactivity and genotype variation with high clopidogrel Dose versus prasugrel: the RESET GENE trial.
Sardella G; Calcagno S; Mancone M; Palmirotta R; Lucisano L; Canali E; Stio RE; Pennacchi M; Di Roma A; Benedetti G; Guadagni F; Biondi-Zoccai G; Fedele F
Circ Cardiovasc Interv; 2012 Oct; 5(5):698-704. PubMed ID: 23048056
[TBL] [Abstract][Full Text] [Related]
32. Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial.
Wiviott SD; Braunwald E; McCabe CH; Horvath I; Keltai M; Herrman JP; Van de Werf F; Downey WE; Scirica BM; Murphy SA; Antman EM;
Lancet; 2008 Apr; 371(9621):1353-63. PubMed ID: 18377975
[TBL] [Abstract][Full Text] [Related]
33. Mortality benefit with prasugrel in the TRITON-TIMI 38 coronary artery bypass grafting cohort: risk-adjusted retrospective data analysis.
Smith PK; Goodnough LT; Levy JH; Poston RS; Short MA; Weerakkody GJ; Lenarz LA
J Am Coll Cardiol; 2012 Jul; 60(5):388-96. PubMed ID: 22633653
[TBL] [Abstract][Full Text] [Related]
34. A randomised trial on platelet function-guided de-escalation of antiplatelet treatment in ACS patients undergoing PCI. Rationale and design of the Testing Responsiveness to Platelet Inhibition on Chronic Antiplatelet Treatment for Acute Coronary Syndromes (TROPICAL-ACS) Trial.
Sibbing D; Aradi D; Jacobshagen C; Gross L; Trenk D; Geisler T; Orban M; Gori T; Hadamitzky M; Merkely B; Kiss RG; Komócsi A; Dézsi CA; Thalmeier A; Löw A; Holdt L; Teupser D; Ince H; Felix SB; Parma R; Malek L; Horstkotte J; Baylacher M; Schwinger R; Rieber J; Mudra H; Hausleiter J; Huber K; Neumann FJ; Koltowski L; Huczek Z; Mehilli J; Massberg S;
Thromb Haemost; 2017 Jan; 117(1):188-195. PubMed ID: 27652610
[TBL] [Abstract][Full Text] [Related]
35. Prasugrel hydrochloride for the treatment of acute coronary syndromes.
Lhermusier T; Waksman R
Expert Opin Pharmacother; 2015 Mar; 16(4):585-96. PubMed ID: 25633751
[TBL] [Abstract][Full Text] [Related]
36. Switching from high-dose clopidogrel to prasugrel in ACS patients undergoing PCI: a single-center experience.
De Luca G; Verdoia M; Schaffer A; Suryapranata H; Parodi G; Antoniucci D; Marino P
J Thromb Thrombolysis; 2014 Oct; 38(3):388-94. PubMed ID: 24659130
[TBL] [Abstract][Full Text] [Related]
37. Comparison of P2Y12 receptor inhibition by clopidogrel and prasugrel in patients undergoing percutaneous coronary intervention.
Haq MM; Ahsan CH; Amin MN; Karim MR; Ali ML; Khan SR; Chowdhury MZ; Mansur M; Millat MH; Rashid MA
Bangladesh Med Res Counc Bull; 2013 Dec; 39(3):139-45. PubMed ID: 26118162
[TBL] [Abstract][Full Text] [Related]
38. Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trial.
Murphy SA; Antman EM; Wiviott SD; Weerakkody G; Morocutti G; Huber K; Lopez-Sendon J; McCabe CH; Braunwald E;
Eur Heart J; 2008 Oct; 29(20):2473-9. PubMed ID: 18682445
[TBL] [Abstract][Full Text] [Related]
39. Population pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in aspirin-treated patients with stable coronary artery disease.
Ernest CS; Small DS; Rohatagi S; Salazar DE; Wallentin L; Winters KJ; Wrishko RE
J Pharmacokinet Pharmacodyn; 2008 Dec; 35(6):593-618. PubMed ID: 19023649
[TBL] [Abstract][Full Text] [Related]
40. Treatment patterns and outcomes in patients undergoing percutaneous coronary intervention treated with prasugrel or clopidogrel (from the Swedish Coronary Angiography and Angioplasty Registry [SCAAR]).
Damman P; Varenhorst C; Koul S; Eriksson P; Erlinge D; Lagerqvist B; James SK
Am J Cardiol; 2014 Jan; 113(1):64-9. PubMed ID: 24169009
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
